PeptideStack
5.2kquestions
20kanswers
220users

Does HJ issue lot-specific documentation, or a batch certificate?

Asked 25 Mar 2025Modified 13 months agoViewed 17k times
5

The lot number on the vial matches the certificate, which at least rules out the easy problem.

I would like to know the limits of what can be inferred from this.

What I am trying to avoid is over-reading a single result, which I have done before.

What would I need in addition before this supported a decision?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
IP
askedivo_paunovic15k1825 Mar 2025

5 Answers

Accepted answer first, then by votes
48

Accepted answer

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 3 Jul 2025 by Dr_Ilse_Vandenberg — added a caveat about sampling

shareimprove this answerflag
DV
answered · acceptedDr_Ilse_Vandenberg78k24817 Jun 2025
3I tested this on two lots and got the same answer, so at least it reproduces. – vialroom 7 months ago
4The timing signature is the useful part. Everything else is confounded. – rania_haddad 9 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
17

Two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 3 Jul 2025 by charge_state_3 — corrected a unit error in the worked example

shareimprove this answerflag
C3
answeredcharge_state_339k4828 Jun 2025
12

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
IB
answeredines_brandt93k24826 May 2025
2Thank you — the worked example is what makes this usable. – aine_mulcahy 9 months ago
3Related: the same reasoning applies to the counter-ion question. – s_bhattacharya 36 days ago
add a comment
9

It helps to be literal here: start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
SG
answeredsinead_gaffney14k286 Jun 2025
2Worth adding that the method section is where the answer usually is. – Dr_Priya_Raghunathan 6 months ago
add a comment
7

In practice, the honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
NT
answeredn_takahashi36k383 Apr 2025
6This is the first explanation of that which has actually made sense to me. – leah_ferrers 4 months ago
7Note that the label instructions differ between agents on precisely this point. – bufferline42 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.